Collegium Pharmaceutical, Inc: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Feb 23, 2023 and accepted by EDGAR at Feb 23, 2023, 16:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-10-01 to 2022-12-31 | $129.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2022-01-01 to 2022-12-31 | $463.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-10-01 to 2022-12-31 | $79.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 12 months2022-01-01 to 2022-12-31 | $254.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2022-10-01 to 2022-12-31 | $49.8m | us-gaap:GrossProfit |
| Gross profit | 12 months2022-01-01 to 2022-12-31 | $209.5m | us-gaap:GrossProfit |
| Research and development | 12 months2022-01-01 to 2022-12-31 | $4.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-10-01 to 2022-12-31 | $38.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2022-01-01 to 2022-12-31 | $172.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-10-01 to 2022-12-31 | $11.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2022-01-01 to 2022-12-31 | $33.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-10-01 to 2022-12-31 | $20.6m | us-gaap:InterestExpense |
| Interest expense | 12 months2022-01-01 to 2022-12-31 | $63.2m | us-gaap:InterestExpense |
| Income tax | 3 months2022-10-01 to 2022-12-31 | −$592.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2022-01-01 to 2022-12-31 | −$3.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-10-01 to 2022-12-31 | −$7.2m | us-gaap:NetIncomeLoss |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$25.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-10-01 to 2022-12-31 | −$0.21 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | −$0.74 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-10-01 to 2022-12-31 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$0.74 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-10-01 to 2022-12-31 | 33,582,202 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 33,829,495 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | $124.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $1.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2022-01-01 to 2022-12-31 | $14.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-12-31 | $173.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $420.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $1.17bn | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $433.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $979.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-12-31 | $194.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-23-001900. Last ingested by Listed: Nov 5, 2026, 12:06 ET. Listed shows no prices and gives no investment advice.